AN EVEROLIMUS DRUG ELUTING STENT SYSTEM
“Unique Stent design together with proven efficacy of everolimus drug & bioresorbable polymers resulted into ETERNIA NEXA with excellent safety & efficacy profile"
Enhanced Outcomes Attributed by Clinically Proven Everolimus Drug
Everolimus drug being more lipophilic than other limus family drug penetrates rapidly at the target lesion and provides rapid cell inhibitory action. Everolimus stents are well proven to show less restenosis, stent thrombosis and periprocedural myocardial infarction compared to an earlier generation of Drug-eluting stents
- An enhanced stent delivery system brings exceptional performance in complex lesions & Challenging anatomy.
- Unique shaft specifically engineered to enhance overall push ability and trackability.
- Unique coating technology to deliver ultimate speed reliability.
- Higher tensile strength polymer tubing to improve kink resistance & retain the flexible performance
of the catheter
Drug Release Kinetics
ETERNIA NEXA has proven drug release kinetics. The initial burst of everolimus is followed by a sustained release for up to 40 days. Bioresorbable polymers completely degrade by hydrolysis & enzymatic the degradation which is eventually excreted from the body in form of CO2 and H20
|Design:||Hybrid Open and Closed Cell Design|
|Material:||L 605 Cobalt Chromium|
|Length(mm):||8 to 47|
|Diameter(mm):||2.00, 2.25, 2.50, 2.75,3.00, 3.50, 4.00, 4.50|
|Strut Thickness:||65 µm|
|Strut Width:||Proximal / Distal : 85 µm & Mid Cells: 70µm|
|Crossing profile:||1 mm|
|Guiding Catheter:||5 Fr Compatible|